Anebulo is developing selonabant, a reversal agent for cannabis induced toxicities. Acute cannabis exposure in younger children has a profoundly different toxic effect compared to adults or adolescents. Its is not simply a younger version of adolescent or adult intoxication.
These effects potentially lead to prolonged hospitalization, ICU admission, invasive diagnostic procedure, and intubation. There are no approved treatments for this condition.
Expanded Access Policy
At Anebulo Pharmaceuticals, we are dedicated to the development of innovative treatments for cannabis-induced toxicity, such as acute cannabis-induced CNS depression in children, acute cannabinoid intoxication (“ACI”) in adults, and the broader landscape of acute cannabis-induced conditions.
Currently, Anebulo is focused on bringing a potential therapy to patients as quickly and efficiently as possible and does not make its unapproved drug available on an expanded access basis.
You can find additional information about Anebulo’s ongoing clinical trials on our website and by accessing https://clinicaltrials.gov.
If you have any questions regarding potential participation in Anebulo’s clinical trials or about this expanded access policy, please contact us.
As authorized by the 21st Century Cures Act, Anebulo may revise this policy at any time.
